S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Arvinas (ARVN) Stock Price, News & Analysis

$34.72
+0.43 (+1.25%)
(As of 04/19/2024 ET)
Today's Range
$33.63
$34.81
50-Day Range
$33.44
$52.31
52-Week Range
$13.57
$53.08
Volume
944,327 shs
Average Volume
512,518 shs
Market Capitalization
$2.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.73

Arvinas MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
72.0% Upside
$59.73 Price Target
Short Interest
Bearish
12.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.00mentions of Arvinas in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$404,489 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.02) to ($4.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.65 out of 5 stars

Medical Sector

421st out of 907 stocks

Pharmaceutical Preparations Industry

190th out of 424 stocks

ARVN stock logo

About Arvinas Stock (NASDAQ:ARVN)

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

ARVN Stock Price History

ARVN Stock News Headlines

Arvinas, Inc. (ARVN)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Up 8.6% in March
Arvinas (NASDAQ:ARVN) Shares Gap Up to $36.73
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Arvinas gets new chief medical officer
Arvinas gets new chief medical head
Arvinas: Behind The Huge Rally
Piper Sandler Keeps Their Buy Rating on Arvinas Holding Company (ARVN)
Navigating 7 Analyst Ratings For Arvinas
Arvinas: Q4 Earnings Insights
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/21/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
445
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.73
High Stock Price Target
$90.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+72.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
16 Analysts

Profitability

Net Income
$-367,300,000.00
Net Margins
-185.09%
Pretax Margin
-463.57%

Debt

Sales & Book Value

Annual Sales
$78.50 million
Book Value
$11.99 per share

Miscellaneous

Free Float
66,566,000
Market Cap
$2.37 billion
Optionable
Optionable
Beta
1.94
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. John G. Houston Ph.D. (Age 64)
    Chairperson, CEO & President
    Comp: $1.08M
  • Dr. Ian Taylor Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $692k
  • Dr. Randy Teel Ph.D. (Age 44)
    Interim CFO & Treasurer
  • Mr. David K. Loomis M.B.A. (Age 50)
    VP, Principal Accounting Officer & Chief Accounting Officer
  • Mr. Jeff Boyle
    Vice President of Investor Relations
  • Mr. Jared M. Freedberg J.D. (Age 55)
    General Counsel & Corporate Secretary
  • Mr. Steve Weiss (Age 54)
    Senior VP & Chief Human Resources Officer
  • Dr. John A. Grosso Ph.D. (Age 67)
    Senior Vice President of R&D Technical Operations
  • Ms. Angela M. Cacace Ph.D. (Age 56)
    Senior Vice President of Neuroscience & Platform Biology
  • Mr. John P. Northcott (Age 46)
    Chief Commercial Officer

ARVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price target for 2024?

16 Wall Street research analysts have issued 12 month price targets for Arvinas' stock. Their ARVN share price targets range from $20.00 to $90.00. On average, they predict the company's share price to reach $59.73 in the next twelve months. This suggests a possible upside of 72.0% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2024?

Arvinas' stock was trading at $41.16 at the start of the year. Since then, ARVN stock has decreased by 15.6% and is now trading at $34.72.
View the best growth stocks for 2024 here
.

Are investors shorting Arvinas?

Arvinas saw a increase in short interest in March. As of March 31st, there was short interest totaling 8,600,000 shares, an increase of 8.6% from the March 15th total of 7,920,000 shares. Based on an average trading volume of 735,200 shares, the days-to-cover ratio is presently 11.7 days.
View Arvinas' Short Interest
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings data on Tuesday, February, 27th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($1.15) by $1.38. The business had revenue of ($43.10) million for the quarter, compared to the consensus estimate of $38.91 million. Arvinas had a negative trailing twelve-month return on equity of 70.24% and a negative net margin of 185.09%. During the same quarter in the prior year, the business posted ($1.56) earnings per share.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

Arvinas (ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (0.30%), Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.04%), Allspring Global Investments Holdings LLC (0.02%) and Cullinan Associates Inc. (0.01%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARVN) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners